Clinical Trials Search
Somatostatin receptor expression in poorly-differentiated neuroendocrine carcinomas of the GI tract: analysis using 68Ga-dotatate PET scan
There are very limited data on somatostatin-receptor expression in poorly differentiated neuroendocrine carcinomas and somatostatin receptor imaging is rarely performed in this population. A high percentage of patients with high SUV uptake (>liver) would indicate that radiolabeled somatostatin analog therapy may be worthy of further study in this patient population.
1. Percentage of patients with uniformly positive 68Ga-dotatate PET (positivity defined as SUV uptake > liver for all tumors at least 1cm in size). 2. Percentage of patients with no uptake, heterogeneous uptake (tumors showing uptake above and below normal liver), low uptake (max SUV¡Ü liver in all tumors), high uptake (max SUV > 2x liver), very high uptake (max SUV¡Ý kidney or spleen)